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Abstract
Purpose—Anticancer drug development is inefficient, but genetically engineered murine models
(GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro
and xenograft systems.
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Experimental Design—We assessed the activity of 16 treatment regimens in a RAS-driven,
Ink4a/Arf-deficient melanoma GEMM. In addition, we tested a subset of treatment regimens in
three breast cancer models representing distinct breast cancer subtypes: claudin-low (T11 OST),
basal-like (C3-TAg GEMM), and luminal B (MMTV-Neu GEMM).
Results—Like human RAS-mutant melanoma, the melanoma GEMM was refractory to
chemotherapy and single-agent small molecule therapies. Combined treatment with AZD6244
[mitogen-activated protein–extracellular signal-regulated kinase kinase (MEK) inhibitor] and
BEZ235 [dual phosphoinositide-3 kinase (PI3K)/mammalian target of rapamycin (mTOR)
inhibitor] was the only treatment regimen to exhibit significant antitumor activity, showed by
marked tumor regression and improved survival. Given the surprising activity of the "AZD/BEZ"
combination in the melanoma GEMM, we next tested this regimen in the "claudin-low" breast
cancer model that shares gene expression features with melanoma. The AZD/BEZ regimen also
exhibited significant activity in this model, leading us to testing in even more diverse GEMMs of
basal-like and luminal breast cancer. The AZD/BEZ combination was highly active in these
distinct breast cancer models, showing equal or greater efficacy compared with any other regimen
tested in studies of over 700 tumor-bearing mice. This regimen even exhibited activity in
lapatinib-resistant HER2+ tumors.
Conclusion—These results show the use of credentialed murine models for large-scale efficacy
testing of diverse anticancer regimens and predict that combinations of PI3K/mTOR and MEK
inhibitors will show antitumor activity in a wide range of human malignancies.
Introduction
The standard anticancer drug development pipeline largely relies on in vitro and xenograft
assays to determine efficacy of candidate antitumor agents. This system is suboptimal as
evidenced by the very high attrition rates of would-be cancer therapeutics, even in the era of
rationally targeted therapies (1–4).In particular, failure at the phase II and phase III stages of
human testing is common, resulting from a lack of antitumor efficacy in humans. Current
drug development practices expose patients to ineffective and toxic agents, distract clinical
trialists from the development of effective therapies, and force the pharmaceutical industry
to subsidize the inordinate costs of late-stage failures. Thus, the preclinical assessment of
efficacy is perhaps the major present challenge for the development of novel anticancer
therapeutics.
Genetically engineered mouse models (GEMMs) may pose some advantages over traditional
systems for this purpose (2, 5–7). In particular, a few groups have showed specific examples
where GEMMs have been able to recapitulate clinical trial results of select agents or have
predicted clinical outcomes before human testing has been completed.In one of the earliest
comparisons, GEMMs predicted the lack of efficacy of PPAR-γ inhibitors in colon cancer
(8, 9) whereas xenograft models predicted the opposite result (10). In addition, although
xenograft models do not predict the influence of K-RAS mutations on response to EGFR-
directed therapies and chemotherapy (11), recent analysis assessing the therapeutic response
in K-Ras mutant GEMMs has found these models faithfully recapitulate the known clinical
outcomes seen in patients (12). Despite these promising series, there has not been a
comprehensive assessment of GEM models versus traditional preclinical efficacy testing.
The GEMM approach until recently has been hampered by a variety of factors relating to
experimental logistics, intellectual property, and other nonscientific concerns (covered in
ref. 2). As these impediments to GEMM testing have been largely resolved, we and others
have turned to the large-scale testing of novel and traditional therapeutics in credentialed
and faithful murine models of human cancers.
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We believe RAS-driven tumors (e.g., melanoma, carcinomas of colon, pancreas, and lung)
represent a particular clinical need. As mutations of K-, N-, or H-RAS occur in 15% to 30%
of all human cancers (see Compilation of Somatic Mutations in Cancer, ref. 13), RAS
activation represents the foremost "undrugged" tumor-driver in cancer biology. Moreover,
RAS mutation is associated with adverse outcomes in several tumor types, and targeted
approaches for mutant RAS are lacking. For example, in melanoma, although mutations of
B-RAF are more common (43%), mutations of N-, K-, and H-RAS are also frequent in
human disease (19%, 2%, and 1%, ref. 14), and RAS-mutant tumors exhibit a worsened
prognosis compared with RAF-mutant disease (15). For these reasons, we initially elected to
focus on Ras-mutant tumors, particularly melanoma where easy serial assessment offers
advantages for large-scale drug testing. Toward that end, we used a previously established
GEMM of RAS-driven melanoma (Tyr-H-Ras (G12V) Ink4a/Arf−/− herein referred to as
"TRIA"; ref. 16) that is favorable for therapeutic testing (see Materials and Methods).
In this model, we tested all cytotoxic agents reported to have single-agent activity in
melanoma, as well as novel therapeutics that have been of interest in this disease. In
particular, we included agents thought to be "RAS-specific" alone or in combination, as well
as combined therapy with AZD6244/BEZ235, a regimen previously shown to have activity
in murine models of RAS-driven lung cancer (17). Given the unexpected results in murine
melanoma, we further studied the efficacy of AZD6244/BEZ235 in a related breast cancer
model, and then even more diverse breast cancer GEMMs. These results in more than 700
tumor-bearing mice suggest combined inhibition of phosphoinositide-3 kinase (PI3K)/
mammalian target of rapamycin (mTOR) and mitogen-activated protein–extracellular




All animal experiments were carried out with approval of the University of North Carolina
Institutional Animal Care and Use Committee. Tyr-HRas(G12V) Ink4a/Arf−/− mouse model
of melanoma was studied (16). This model features an activated H-Ras codon 12 mutant
transgene integrated on the Y-chromosome combined with germline Ink4a/Arf inactivation,
and is faithful to the human tumor genetics: RAS activation is present in ∼20% of human
melanoma, and Ink4a/Arf loss is observed in 60% to 90% of melanoma. By crossing Tyr-
Ras Ink4a/Arf−/− males with Ink4a/Arf−/− females, cohort were produced where no
genotyping is required (all the males get cancer) and all the progeny mice are useful (the
males develop tumors and the females are used for future breeding). This model is also
addicted to persistent RAS signaling (18).
In addition to the TRIA melanoma model, we studied 2 GEM models of breast cancer: the
C3-TAg transgenic mouse model of basal-like breast cancer (19) and the MMTV-c-neu
mouse model (20). The C3-TAg transgenic mouse model of basal-like breast cancer (19)
contains a recombinant gene expressing the simian virus 40 early region transforming
sequence (SV40 large T antigen), which has been shown to inactivate both p53 and RB (21–
23). The MMTV-c-neu mouse model of HER2+ breast cancer (20) expresses c-neu (the
mouse ortholog of human HER2) driven by the mouse mammary tumor virus (MMTV)
promoter and has been shown to represent a model of the luminal breast cancer subtype
(24).
Where necessary, we have included an OST models (e.g., the T11 model; ref. 25) when an
adequate GEMM could not be identified for the given tumor type (e.g., Claudin-low breast
cancer). When syngeneic transplant models are used, they are still assessed using the other
Roberts et al. Page 3













described practices of the MP1U (e.g., for tumor regression, large cohort size, etc.). When
tumors were noted to be approximately 0.2 cm2 in size, animals were treated as described
and tumor response was assessed by weekly caliper measurements. Data in Fig. 1 are
normalized to tumor size at the time of therapy initiation, with volumes calculated using the
formula Volume=[(width)2 × length]/2. Tumor-bearing mice were euthanized at the
indicated times for morbidity, tumor ulceration, or tumor size of more than 2.0 cm in
diameter.
Compounds
Compounds were obtained from commercial sources, by custom synthesis, or rarely under
material transfer agreement from an industry partner. The MP1U has focused on
conventional chemotherapeutic agents and small molecule agents rather than monoclonal
antibodies because of interspecies differences in tumor epitopes ABT-888, AZD-6244, and
FTS (S-trans,trans-farnesylthiosalicylic acid) were synthesized by the Center for Integrative
Chemical Biology and Drug Discovery (CICBDD) at the University of North Carolina.
Carboplatin (Hospira, Inc.), cyclophosphamide (Hospira, Inc.), doxorubicin (Bedford
Laboratories), etopo-side (Teva Parenteral Medicines, Inc.), and paclitaxel (Ivax
Pharmaceuticals, Inc.) were obtained from their respective manufacturers and handled as per
standard practice. Erlotinib (Genentech, Inc.), lapatinib (GlaxoSmithKline), suni-tinib
(Pfizer, Inc.), temozolomide (Merck) were obtained from clinical commercial sources.
BEZ-235 and lonafarnib was obtained under material transfer agreements (MTA) with
Novartis AG and Schering-Plough (now Merck/ Schering-Plough) respectively. In accord
with these MTAs, pharmaceutical partners were shown these data before submission for
publication, but had no role in the performance of these studies or the preparation of the MS.
Dosing and schedule
A major hurdle for the comprehensive undertaking was establishing the dose and schedule
for each treatment regimen that we tested. The agent-specific approach to determine
schedule and dose is extensively described in (Supplementary Table S1). In brief,we used
published work to identify doses for well-studied agents (e.g., doxorubicin), and direct
pharmacokinetic (PK) measurement in some instances (e.g., PD0332991, paclitaxel,
carboplatin, dasatinib, data not shown).When neither of these approaches was possible,
compounds were dosed at the maximally tolerated dose (MTD) as determined in the MP1U
or reported by pharmaceutical partners. Most regimens required extensive dose finding in
the MP1U before efficacy studies. Only results from mice treated at optimal dosing
regimens are shown in the response figures. Results using dosing regimens with inadequate
exposure or poor tolerability are excluded.
Carboplatin (Hospira, Inc.) was given by intraperitoneal (i.p.) injection and paclitaxel (Ivax
Pharmaceuticals, Inc.) was given intravenous injection (i.v.). For temozolomide, erlotinib,
and ABT-888, varying doses were used to confirm strain- and age-specific maximally
tolerated dose. For oral drugs, the compound of interest was milled into chow by Research
Diets, Inc. Chow was weighed daily for 1 week to calculate average daily intake.
Mice were treated with cytotoxic chemotherapy agents (e.g., carboplatin) once weekly for
21 days. A minimum of 1 week off treatment was given to all mice. Treatment only resumed
when one of 2 conditions was met: (1) the primary tumor progressed by at least 2 mm in any
direction by caliper measurement or (2) a secondary tumor became palpable. Orally
available biologic inhibitors were dosed continuously with no dose interruption. Inhibitors
were only removed in the case of complete regression of the tumor, or for weight loss. In the
case of cytotoxic chemotherapy used with an oral small molecule inhibitor, the cytotoxic
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agent was dosed once weekly for 21 days and stopped until progression, whereas small
molecule inhibitors were dosed continuously.
Response criteria
Tumor volume was calculated from 2-dimensional measurements. The percent change in
volume at 14 and 21 days was used to quantify response. SD, PR, and CR were defined as
per RECIST criteria. Survival was measured from first day of drug treatment.
Murine model cluster
Murine models of mammary carcinoma (GSE3165, GSE27101; refs. 24 and 26) and
melanoma (GSE34866) were combined into a single dataset and compared for
transcriptional similarities. Samples within each of these published datasets were analyzed
on 3 different Agilent array platforms (22K, 4 × 44K, or 4 × 180K). Using normalization
methods described to correct for platform effects between 22K and 4 × 44K platforms (26),
we used 10 microarrays (5 MMTV-c-neu and 5 C3(1)-TAg) from each array type (30
microarrays total) to calculate a median, probe-level normalization factor using R v2.12.2.
These arrays were chosen based on their high correlation to each other within each array
type when clustered using a previously defined intrinsic gene list (24) to eliminate outliers
from the array type correction. Principle component analysis (PCA) was used to verify
proper normalization of the platforms. Unpublished MMTV-c-neu and C3(1)-TAg tumors
used for platform correction were collected and microarray processed using methods
previously described (24, 26). These arrays were uploaded to the Gene Expression Omnibus
under series GSE35722 and to the University of North Carolina Microarray Database (27).
To identify transcriptional similarities between murine models of mammary carcinoma and
melanoma, an unsupervised cluster analysis was carried out using any probe with a log2
absolute expression value greater than 2 on at least 3 microarrays (2,584 probes) using
Cluster v3.0 (28). The data were viewed using Java Treeview v1.1.5r2 (29).
Cell culture and western blotting
Tumor-derived C3Tag and TRIA cell lines were grown in DMEM supplemented with 10%
FBS and 1% penicillin/ streptomycin. Tumor-derived T11 cells were grown in RPMI
supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were lysed on ice for 20
minutes in lysis buffer containing 50 mmol/L HEPES (pH 7.5), 0.5% Triton X-100, 150
mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 10 mmol/L sodium fluoride, 2.5 mmol/L
sodium orthovanadate, 1× protease inhibitor cocktail (Roche), and 1%each of phosphatase
inhibitor cocktails 2 and 3 (Sigma). Cell lysate centrifuged for 15 minutes (13,000 rpm) at
4°Cand the supernatant was collected. Proteins from cell lysates were separated by SDS-
PAGE chromatography, transferred to nitrocellulose membranes, and probed with the
indicated primary antibodies. Antibodies recognizing pAKT (S473), pERK1/2 (T202/Y204),
and phospho-MEK1/2 antibody (S217/S221) were obtained from Cell Signaling
Technology. The antibody for ERK2 was obtained from Santa Cruz Biotechnology. HRP-
anti-rabbit secondary antibody was obtained from Jackson Immunoresearch Laboratories.
Western blots were incubated with SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific) and exposed to film.
Statistics
Unless otherwise noted, comparisons are made with t test or 1-way ANOVA, with
Bonferroni correction for multiple comparisons where appropriate. P values of less than 0.05
are considered significant. Error bars represent ±SEM.
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We tested 11 distinct single agents in 16 treatment regimens in the TRIA model, and a
subset of these treatment regimens were also tested in models of breast cancer representing
distinct clinical subtypes in the UNC Mouse Phase I Unit (MP1U). In a contemporaneous
study, additional treatment regimens were tested in the 3 breast cancer models (Usary and
colleagues, submitted), and the most active regimens from that study were compared with
AZD/ BEZ in this work. All FDA-approved and experimental compounds used in this work
are described in Supplementary Table S1. Relevant features of all MP1U testing are:
1. The use of credentialed GEMMs. For the breast models, credentialing was
accomplished with expression profiling (see refs. 24 and 26). For melanoma, model
choice was guided by RAS-dependence and other experimental features (see
Materials and Methods).
2. The use of large (10–25) cohorts of tumor-bearing animals per therapeutic cohort,
with assessment of both novel and approved agents in each disease type. Large-
scale testing of combinations in the breast models will be reported elsewhere
(Usary et al., submitted).
3. The serial assessment for tumor response as opposed to measures of
nonprogression (e.g., tumor growth inhibition, TGI), as TGI does not mimic
acceptable measures of efficacy in humans. The 2 primary endpoints described in
this work are percent change in tumor volume at day 21 and overall survival (both
calculated as described in the Materials and Methods).
Choice of murine model for efficacy testing in this work was initially guided by RAS-
dependence, but given the activity of a single regimen,we subsequently turned to more
diverse GEM models.
Drug testing in Ras-mutant melanomas
Current treatment approaches for advanced melanoma are largely ineffective, with no
targeted agents for RASmutant disease. Temozolomide provides a meager 12% response
rate (30), and even newly approved ipilimumab offers only a modest 3.5-month survival
advantage (31). To test different regimens in a GEM model of human RAS-driven
melanoma, we generated cohorts of 10 to 20 inbred male TRIA mice. Mice were serially
assessed for tumors, and treatment regimens were initiated in tumors at a minimum size of
25 mm3. In total, 15 single-agent or combination regimens and total body irradiation (single
dose TBI; 7.5 Gy) were tested (Fig. 1A). Regimens of cytotoxic therapeutics with activity in
human melanoma such as temozolomide and carboplatin–paclitaxel were not effective at
inducing tumor response by 21 days of therapy. Similarly, small molecule agents such as
sunitinib, lapatinib, and potential anti-RAS approaches [S-trans, trans-farnesylthiosalicylic
acid (FTS) and lonafarnib, a farnesyltransferase inhibitor] were ineffective in this model as
single agents. Response rates of the tested agents in the TRIA model using a modified
version of Response Evaluation Criteria In Solid Tumor (RECIST) correlated with the
antitumor efficacy of these agents in human melanoma (Table 1). Therefore, like human
RAS-mutant melanoma, this model was highly refractory to therapy and treatment studies in
this GEMM correlate with an agent′s activity in human disease.
Therapeutic response, defined as tumor regression and survival improvement, was observed
with only one treatment regimen in the TRIA GEMM. The co-administration of AZD6244
(an MEK inhibitor) and BEZ235 (a dual PI3K/ mTOR inhibitor) resulted in significant
tumor regression at 21 days in the majority of mice (Fig. 1A). Overall, the dual AZD/BEZ
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treatment cohort had a 27.5% (95% CI = −4.5–59.4) median increase in tumor volume at 21
days compared with 217.5% (95%CI= 151.6–283.4) increase in the untreated cohort (P <
0.0001). Neither AZD nor BEZ exhibited significant activity at day 21 as a single agent. A
"waterfall plot" of best response (21 days or later) showed that AZD/BEZ treatment resulted
in partial response (PR) or stable disease (SD) in 12 of 19 animals (63%) (Fig. 1B). This
observation suggests that inhibition of single RAS downstream effector pathways, MEK or
PI3K, in isolation is not sufficient to induce tumor regression, but concomitant MEK and
PI3K/mTOR inhibition can cooperatively produce tumor regression in most RAS-driven
melanomas.
The regimens determined to be most active in the 21-day response assay were given in long-
term survival experiments (Fig. 1C). Although every agent thus far tested in the MP1U that
produces a reduction in tumor growth at 21 days also enhances survival, the converse is not
true. Therefore, an overall survival endpoint was assessed on therapy given that some agents
showing only modest activity at 21 days still produce a significant survival benefit (see, e.g.,
carboplatinpaclitaxel; Fig. 1A and C). Intravenous carboplatin–paclitaxel and oral single-
agents sunitinib, AZD, and BEZ all led to modest improvements in survival compared with
untreated animals, with single-agent BEZ the best of this group increasing the duration of
median survival by 70% (21–36 days, P < 0.001). In accord with the 21-day response data,
however, AZD/BEZ treatment afforded far greater clinical benefit than any other regimen,
increasing median survival by 205% compared with untreated animals (21–64 days, P <
0.001). These data show that the marked antitumor activity observed at 21 days or later (Fig.
1B) translates into a tripling of median survival in mice with established, high-grade
melanomas.
Testing of AZD/BEZ in a model of claudin-low breast cancer
After identifying the potent activity of the AZD/BEZ drug combination in melanoma, we
turned to a model of "clau-din-low" breast cancer (25). This choice was motivated by the
unexpected finding that claudin-low breast models show expression features in common
with melanoma. For example, unsupervised analysis of 13 murine mammary carcinoma
models (24, 26) and 4 murine melanoma models showed that the melanoma samples
clustered with claudin-low tumors (Fig. 2A). As seen in human claudin-low samples (25),
murine melanomas exhibited low expression of claudins (e.g., Cldn3, Cldn4, Cldn7) and
cytokeratins (e.g., Krt5, Krt14, Krt17) and increased expression of genes associated with
epithelial-to-mesenchymal transition [e.g., Snal1/2, Zeb2, Cdh1 (E-cadherin); Fig. 2B and
C). Both murine tumor types were also characterized by increased expression of
inflammatory/immune genes compared with other breast models (e.g., IL6, IL33, Ccl2; Fig.
2D). Melanomas differed from claudin-low breast tumors in the expression of melanocyte
lineage genes such as Pax3 as well as transcripts expressed in melanoma as opposed to
breast cancer [Gas7 and Cdh2 (N-cadherin)]. Using a recently described metric to calculate
a "differentiation score" in breast cancer (higher score = more differentiated; ref. 25),
melanoma, and claudin-low models showed similarly low scores (Fig. 2F), suggestive of
expression profiles more similar to mammary stem cells than differentiated luminal cells.
Given these shared transcriptional features with the TRIA model, we elected to further test
AZD/BEZ in the claudin-low breast cancer model.
We have not identified a faithful GEM model of the claudin-low breast cancer subtype that
only gives rise to just this tumor subtype, therefore have taken to the analysis of genomically
selected orthotopic, syngeneic transplant (OST) models. The T11 model derives from the
serial orthotopic transplantation of a murine breast tumor derived from a p53-null mouse
into a syngeneic p53 competent recipient, and features sporadic, somatic K-Ras mutation
(data not shown). Tumors from the T11 model display an RNA expression pattern
characteristic of the human claudin-low disease (Fig. 2 and ref. 26), and are extremely
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aggressive, with the majority of untreated animals surviving less than 21 days from the time
of enrollment in the therapy studies. Therefore, a 14-day rather than 21-day response
endpoint was used to assess activity in this model. As in the TRIA melanoma model, AZD/
BEZ was highly active in the T11 OST model (Fig. 3A compares AZD/BEZ with 4 of the
most active other 16 tested regimens, see also Usary et al., submitted). Although no CRs
were seen in the T11 model, AZD/BEZ treatment caused an SD + PRrate of 62% (Fig. 3B)
and more than doubled median survival compared with untreated animals (from 15 to 36
days, P< 0.0001; Fig. 3C). Compared to other active regimens (sunitinib and carboplatin–
paclitaxel) and single-agent AZD or BEZ, the combination was superior in terms of
response and survival prolongation. Therefore, combined PI3K/mTOR and MEK inhibition
afforded significant clinical benefit in a murine transplantation model of the claudin-low
breast cancer subtype.
Testing of AZD/BEZ in diverse GEM breast cancer models
Given the activity of this regimen in RAS-driven melanoma and claudin-low breast cancer,
we determined the efficacy of this regimen in 2 other 2 breast cancer GEMMs: representing
the basal-like (or BBC, C3-TAg) and luminal (MMTV-c-neu) subtypes of breast cancer.
These models have been previously credentialed by unbiased gene expression analysis that
indicated maximal similarity to their respective human breast cancer subtypes (BBC and
luminal) from a large panel of other GEM breast models (24). The C3-TAg model (19)
harbors a standard transgenic allele with a breast-specific promoter driving overexpression
of the simian virus 40 Large T Antigen (TAg), which inactivates the p53 and RB tumor
suppressors. This model is faithful to human BBC, which frequently features combined RB
and p53 loss (32–36), and C3-TAg and human BBC show common patterns of gene
expression by RNA expression profiling (24, 32). Of relevance to AZD/BEZ testing, tumors
from this model frequently (∼30%), but not always, acquire K-Ras amplification with
progression (37), and haploid loss of K-Ras delays progression in this model (38).
Therefore, a fraction of tumors in this GEMM likely require persistent RAS activation for
tumor maintenance, and we reasoned differential sensitivity to AZD/BEZ might correlate
with K-Ras activation status.
We were surprised, therefore, to note potent activity for the dual AZD/BEZ treatment in
nearly all tumors from this BBC model. As in the TRIA model, AZD/BEZ treatment
resulted in significant tumor regression and improved survival compared with untreated
mice or mice treated with other active therapeutic regimens (Fig. 4A–C). A waterfall plot of
best response (21 days or later) showed SD + PR + CR (SD, stable disease; PR, partial
response; CR, complete response) in 16 of 17 treated mice, indicating a 94% response rate,
with almost half of the treated mice exhibiting CR. This high response rate translated into a
marked survival benefit with median survival increasing by 115% compared with untreated
animals (33–71 days, P < 0.0001). As in the TRIA model, the response rate and survival
advantage of AZD/BEZ was superior to any other regimen tested in this model (of N =15
regimens; Usary et al., submitted; see also Fig. 4A and C). For example, the 2 next most
active regimens (sunitinib or carboplatin–paclitaxel) only modestly extended survival (64%
and 33%) compared with AZD/BEZ. Similarly, neither AZD nor BEZ was nearly as active
in this model as a single-agent therapy compared with combined therapy (Fig. 4A and C).
These data indicate AZD/BEZ induces significant tumor response and extends survival in a
credentialed GEM model of BBC, regardless of the presence or absence of K-Ras
amplification.
Given this lack of general correlation between AZD/BEZ efficacy and Ras mutation in the
C3-TAg model, we considered a model that does not harbor Ras mutation or amplification:
the MMTV-c-neu GEMM. This mouse model of luminal breast cancer features transgenic
expression of the rat ortholog of human HER2 driven by an ER-enhanced breast promoter
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(MMTV; ref. 20). Treatment with AZD/BEZ was also highly active in this model (Fig. 5A –
C), with a PR+ CR rate of 100% (12 of 12), with 5 CRs. Several regimens (e.g., carboplatin–
paclitaxel, lapatinib) induced responses and significantly prolonged survival in this model,
as did single-agent treatment with AZD and BEZ (Fig. 5C, all P < 0.001 in pairwise
comparison with untreated mice). As expected, this model was exquisitely sensitive to
lapatinib (100% CR rate; Fig. 5A and C), a HER2 kinase inhibitor that is FDA-approved for
HER2-amplified breast cancer in humans. Remarkably, however, the AZD/BEZ
combination was better in terms of response than all other regimens except lapatinib (Fig.
5A), and equivalent to or better than lapatinib in terms of survival prolongation, inducing a
striking 400% increase in median survival (29–173 days, P < 0.0001; Fig. 5C). Therefore,
combined PI3K/mTOR and MEK inhibition offers equivalent activity in HER2-driven
GEMM (expressing wild-type RAS) compared to a FDA-approved targeted anti-HER2
agent.
Cross-talk between PI3K and MEK signaling
Although AZD6244 and BEZ235 both showed only modest single-agent activity in the
models studied, the combined AZD/BEZ regimen was highly effective in each of these
models. In an effort to understand the molecular basis for this synergy, cell lines derived
from the tumor models were treated in vitro with AZD6244 (1 µmol/L), BEZ235 (250 nmol/
L), or combinaiton AZD/BEZ (1 µmol/ L/250 nmol/L). Tumor-derived cell lines from
TRIA, T11, and C3-TAg tumors were studied; the MMTV-c-neu model was not considered
as cell lines could not be derived from this model. Cell lines were treated for 24 hours with
the indicated compounds, and analyzed by Western blot for target inhibition (Fig. 6).
Expression of pERK was low in all 3 cell lines, and was not affected by single-agent
AZD6244 treatment. Single-agent AZD6244 treatment produced an increase in
phosphorylation of AKT at serine 473, a site phosphorylated by mTOR.In contrast, single-
agent BEZ235 treatment decreased S473 phosphorylation of AKT, as expected and
consistent with inhibition of mTOR, but also led to a marked increase in phosphorylation of
ERK1/2. Cotreatment with AZD6244 and BEZ235 inhibited phosphorylation of both AKT
and ERK1/2, indicating effective target inhibition. The surprising activation of AKT by
MEK inhibitors and ERK activation by PI3K inhibitors has been reported in other cell types
(39–43), and reflects compensatory feedback loops between these pathways. We believe
these complex inhibitory networks explain the modest activity of PI3K and MEK inhibitors
as single agents in the multiple murine models thus far tested, and also explain the potent
synergy of the combined AZD/BEZ regimen in vivo, which is seen in our in vivo results.
Dual PI3K/MEK inhibition in lapatinib-resistant HER2+ breast cancers
We next turned to an assessment of the AZD/BEZ regimen in the setting of resistant disease.
Given the potent activity of AZD/BEZ in the MMTV-c-neu model,we decided to evaluate
the efficacy of this regimen in tumors that had become completely refractory to lapatinib
therapy. MMTV-c-neu tumors will always respond completely to initial lapatinib therapy
(Fig. 5A), but then resistant tumors will develop on therapy causing progression and death
within 150 days on treatment (Fig. 5C). Given this observation, a model to study lapatinib-
resistant disease was developed as shown in Fig. 7A. In brief, at the time of progression and
while on continuous lapatinib therapy, resistant tumors were harvested and orthotopically
passaged into the mammary fatpad of syngeneic female mice. Tumors were allowed to
establish to a size of at least 5 mm in any one direction before the initiation of lapatinib
rechallenge or second-line treatment. As expected, retreatment with lapatinib in mice
transplanted with lapatinib-resistant tumors was not effective (Fig. 7B and C). Remarkably,
however, combined AZD/BEZ treatment was highly active in lapatinib-resistant disease,
resulting in median tumor reduction of 57% (Fig. 5B, P = 0.007) and increasing survival
290% (from 29 to 113 days, P < 0.001, Fig. 7C) compared with lapatinib retreatment. These
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data show that AZD/BEZ therapy can be effective in tumors chosen for therapeutic
refractoriness to other agents.
To further evaluate the mechanism of lapatinib resistance, we isolated tumors from mice that
were lapatinib naïve, responding to lapatinib treatment, lapatinib resistant, and lapatinib
resistant responding to AZD/BEZ treatment. These tumors were harvested directly from
mice while on therapy, and then analyzed by Western blot for target inhibition. This analysis
showed that lapatinib-resistant tumors exhibited increased phosphorylation of AKT S473
(mTOR target), MEK1/2, and ERK1/2 (Fig. 7D). Treatment of lapatinib-resistant tumors
with AZD/BEZ led to phosphorylation levels of these proteins equivalent to that seen in
lapatinib-sensitive tumors on lapatinib (compare lanes 4 and lanes 2 of Fig. 7D). These data
show that lapatinib resistance occurs in the setting of MEK/ERK and PI3K/ mTOR
activation, explaining the efficacy of the AZD/BEZ regimen even in lapatinib-resistant
disease.
Discussion
In this work, we show that therapeutic testing in GEM and OST models can be carried out in
a medium-throughput manner at reasonable expense to identify unexpected therapeutic
single-agent and combination regimens. We also show potent antitumor activity of
combined therapy with PI3K/mTOR inhibitors and MEK inhibitors in a diverse array of
credentialed GEM and OST models. We showed impressive activity of this regimen in the
RAS-driven melanoma model. Based on a shared gene expression between melanoma and
claudin-low breast tumors, we tested AZD/ BEZ in the T11 OST model, which also harbors
an activating mutation of K-Ras. Given significant activity in this treatment-refractory and
aggressive model, we then turned to 2 additional breast GEM models representing BBC
(C3-TAg mice) and luminal breast cancer (MMTV-c-neu), which are not obligately RAS-
driven. We observed broad and reproducible antitumor activity of the AZD/BEZ regimen in
all of these disparate models, in accord with prior studies in GEM models of NSCLC (17,
44). In aggregate, these studies predict broad antitumor efficacy of combined MEK and
PI3K/mTOR inhibitors in human cancer patients.
This large experience in animal models points to some of the strengths of GEM testing
versus conventional measures to assess preclinical efficacy. For example, certain regimens
(e.g., carboplatin–paclitaxel and sunitinib in TRIA mice) clearly reduced tumor growth
rates, and therefore would score highly in traditional tumor-growth inhibition (TGI) assays.
When assessed by more rigorous standards, however, these regimens were not capable of
inducing tumor regression (Fig. 1A) and produced only modest enhancement of long-term
survival (Fig. 1C). Our results using tumor regression and long-term survival correspond
better to the efficacy of these agents in human patients (Table 1) than predictions based on
TGI in xenograft systems. Also in contrast to xenograft models, we have generally observed
significant heterogeneity among tumors within any given model in terms of rate of growth
and response rates to active regimens. We believe this more faithfully models the human
setting and provides an opportunity to understand primary therapeutic resistance to active
agents, an area of intense ongoing study.
We believe that the implications of this work for human therapeutics are considerable, as
testing of MEK and PI3K/ mTOR inhibitors has already begun in human cancer patients.
Our data showing compensatory activation of ERK signaling by PI3K/mTOR inhibitors and
compensatory activation of AKT by MEK inhibitors explains the observed therapeutic
synergy of the AZD/BEZ combination, and suggest that single-agent trials of these agents
should rapidly give way to combination trials in certain tumor types. Of note, there are
approximately 17 ongoing early phase clinical trials evaluating 14 unique combinations of
Roberts et al. Page 10













MEK and PI3K/mTOR inhibitors, and preliminary results for a few of these novel
combinations have been promising (clinicaltrials.gov; ref. 45). In addition, our data suggest
trials of combined PI3K/mTOR and MEK inhibitors should be opened in a variety of
cancers, and in particular should focus on RAS-mutant cancers for which no effective
targeted approaches exist. Our data also predict that resistance to combined MEK and PI3K/
mTOR inhibition will develop within months of starting therapy (see Figs. 1C, 3C, and 4C),
emphasizing the immediate need to study acquired resistance in human clinical specimens as
well as murine models. Toward that end, these models will provide an excellent platform to
study both de novo and acquired resistance to AZD/BEZ and related combinations. The
finding in lapatinib-resistant tumors of ERK/AKT activation and significant sensitivity to
the AZD/BEZ regimen (Fig. 7B–D) is particularly encouraging. This result suggests that
mechanisms of resistance to HER2 kinase inhibitors still require activation of persistent
downstream HER2 effectors such as PI3K, mTOR, and/or MEK. This observation is
analogous to the finding that resistance to B-RAF inhibitors in melanoma often requires
downstream activation of MEK (reviewed in ref. 46). Similarly, although lapatinib
resistance in HER2-driven breast cancer is imperfectly understood, resistance is frequently
associated with increased activation of the PI3K pathway (reviewed in ref. 47). Therefore,
our results suggest that the AZD/BEZ combination can be active in tumors resistant to other
targeted kinase inhibitors, and also suggest the possibility that early combination of these
agents (e.g., with lapatinib) may limit primary refractory disease and development of
secondary resistance.
A critical question based on these results relates to the toxicity of this regimen. Because of
practical concerns,we do not conduct comprehensive toxicologic assessment of regimens in
the MP1U. We did conduct the serial assessment of animal weights on all treated mice, as
well as monitoring of blood counts in a subset of treated animals, and by these measures,
toxicity of this regimen was manageable. In some mice, brief treatment breaks were given
because of weight loss, and often we observed tumor regrowth during these treatment
breaks, further emphasizing the activity of this regimen. Gratifyingly, the limited amount of
human phase I testing thus far accomplished with combined MEK and PI3K inhibitors
suggests these combinations are not too toxic for human use (48). In summary, our work
predicts broad clinical activity of the combination of MEK and PI3K/mTOR inhibitors in a
large variety of human malignancies with expected tolerable levels of toxicity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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We describe a comprehensive assessment of 16 anticancer therapeutic regimens in
multiple engineered murine model (GEMM) and orthotopic, syngeneic transplant (OST)
cancer model. Aggregate analysis from these studies shows that, in contrast to standard
preclinical efficacy testing (e.g., xenograft models), these faithful models exhibit a high
predictive accuracy of the clinical efficacy of known chemotherapeutic agents used in
melanoma and breast cancer. Moreover, testing of novel agents showed extraordinary
anticancer activity from combined therapy with phosphoinositide-3 kinase (PI3K)/
mammalian target of rapamycin (mTOR) and mitogen-activated protein–extracellular
signal-regulated kinase kinase (MEK) inhibitors. These data have significant implications
for the clinical development of MEK and PI3K/mTOR inhibitors and predict that this
combination will have broad clinical activity across disparate human malignancies.
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RAS-driven melanoma is refractory to standard chemotherapy but is sensitive to combined
PI3K/mTOR/MEK inhibition. TRIA mice were stratified by tumor size and randomly
assigned to a treatment cohort. A, of the 15 treatment regimens tested, combined AZD/ BEZ
treatment was the only regimen that produced tumor regression as measured by percent
change in tumor volume at day 21.B,waterfall plot distribution of tumor response from
combined AZD/BEZ compared with the average tumor size of untreated animals on day 21.
AZD/BEZ response represents the best response seen on day 21 or beyond. Negative values
indicate tumor shrinkage. C, combined AZD/BEZ treatment prolonged median survival
from 21 to 61 days; MS, median survival.
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Transcriptional analysis of murine models of mammary carcinoma and melanoma. A, an
unsupervised cluster of all probes with a log2 absolute expression value greater than 2 on at
least 3 microarrays (2,584 probes). The colored bars correspond to the region of the cluster
for the gene lists in parts C to E. B, highlighted is the location in the dendrogram of the C3-
TAg, MMTV-c-neu, claudin-low (including T11 OST tumors), and melanoma tumors
(including TRIA tumors). Below are markers of the claudin-low subtype as defined by Prat
and colleagues (25). C, a cluster of genes that are downregulated in both claudin-low and
melanoma tumors. D, a cluster of genes that are upregulated in tumors from 6 different
claudin-low and 4 different melanoma models. E, a melanoma specific gene cluster. F, a
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rank of median differentiation scores for tumors from the indicated breast and melanoma
models.
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Combined PI3K/mTOR/ MEK inhibition is the most effective treatment regimen in claudin-
low breast cancer model. T11 mice were stratified by tumor size and randomly assigned to a
treatment cohort. A, combined AZD/BEZ was the most effective treatment regimen as
measured by percent change in tumor volume at day 14. B, waterfall plot distribution of
tumor response from combined AZD/BEZ compared to the average tumor size of untreated
animals on day 14. AZD/ BEZ response represents the best response seen on day 14 or
beyond. Negative values indicate tumor shrinkage. C, combined AZD/BEZ treatment
prolonged median survival from 15 to 32 days; MS, median survival.
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Basal-like breast cancer model is exquisitely sensitive to combined PI3K/mTOR/MEK
inhibition. C3-TAg mice were stratified by tumor size and randomly assigned to a treatment
cohort. A, combined AZD/BEZ was the most effective treatment regimen, resulting in a
median percent change in tumor volume at day 21 of —84%. B, waterfall plot distribution of
tumor response from combined AZD/BEZ compared with the average tumor size of
untreated animals on day 21. AZD/BEZ response represents the best response seen on day
21 or beyond. Negative values indicate tumor shrinkage. C, combined AZD/BEZ treatment
prolonged median survival from 33 to 71 days; MS, median survival.
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A GEM model of luminal breast cancer is exceptionally sensitive to combined PI3K/mTOR/
MEK inhibition. MMTV-c-neu mice were stratified by tumor size and randomly assigned to
a treatment cohort. A, lapatinib and combined AZD/BEZ treatment regimens provide nearly
complete tumor regression as measured by percent change in tumor volume at day 21. B,
waterfall plot distribution of tumor response from combined AZD/BEZ compared with the
average tumor size of untreated animals on day 21. AZD/BEZ response represents the best
response seen on day 21 or beyond. Negative values indicate tumor shrinkage. C, combined
AZD/ BEZ treatment prolonged median survival from 29 to 173 days, whereas lapatinib
prolonged median survival to only 112 days; MS, median survival.
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Inhibition of AZD6244 and BEZ235 targets in tumor-derived cell lines. To evaluate the
molecular response to AZD6244, BEZ235, or combined AZD/ BEZ treatment, tumor-
derived cell lines from TRIA, T11, and C3Tag tumors were treated for 24 hours with
AZD6244 (1 µmol/L) and/or BEZ235 (250 nmol/L) and evaluated by Western blot analysis
for target inhibition. Single-agent AZD led to PI3K activation (as evidenced by increased
S473 phosphorylation of AKT), whereas single-agent BEZ led to ERK activation (as
evidenced by increased phosphorylation of ERK1/2). Combined treatment with AZD/BEZ
produced combined inhibition of the PI3K/mTOR and MEK/ERK pathways.
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Combined PI3K/mTOR/MEK inhibition is an effective treatment regimen in lapatinib
resistant HER2+ breast cancer. A, MMTV-c-neu mice stratified by tumor size and assigned
to continuous treatment with lapatinib were followed until tumors progressed through
treatment. Resistant tumor were harvested and passaged into the mammary fat pad of 6-to 8-
week-old female FVB mice. Following injection, tumors were allowed to reach minimum
size of at least 5 mm in any one-dimension before initiating second line therapy (either
rechallenge of lapatinib or dual AZD/BEZ).B, retreatment with lapatinib has no effect on
tumor growth, whereas the combined AZD/BEZ treatment results in median tumor
regression of −57%, as measured by percent change in tumor volume at day 21. C,
combined AZD/BEZ treatment prolonged median survival from 29 to 113 days; MS, median
survival. D, lapatinib-resistant MMTV-c-neu tumors display upregulated phosphorylation of
AKT, MEK1/2, and ERK1/2. Treatment of mice bearing lapatinib resistant tumors with
AZB/BEZ returns phosphorylation of AKT, MEK1/2, and ERK1/2 to preresistant levels.
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Table 1
RECIST response rates in TRIA mice versus human melanoma
Regimen
Mean day 0 tumor
volume (mm3)
Mean day 21 tumor
volume (mm3)
RECIST response
rate (CR + PR + SD)
Reported human response
rates for melanoma
Untreated 83 322   0%
Carboplatin 89 217 21% 14%–23%
Paclitaxel 62 182 21% 14–18%
Carboplatin/paclitaxel 41   97 38% 19%–47%
Temozolomide 88 266 10% 15% (10%–17%)
Sunitinib 63 115 32% 33%
AZD6244/BEZ235 53   29 63% Unknown
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